Why the study?
Does high-dose aspirin moderate diabetes-induced changes in heart glycogen and glucose metabolism in rats?
Does high-dose aspirin moderate diabetes-induced changes in heart glycogen and glucose metabolism in rats?
High-dose aspirin moderates diabetes-induced metabolic changes in the rat heart by reducing glycogenogenesis and inhibiting the depression of glycolysis.
May moderate diabetic cardiac glycogen in rat models; leaves open human translation.
Aspirin (ASA), as a multifunctional drug has been used as a hypoglycaemic agent in the treatment of diabetes and severe hyperglycaemia and has been established as a secondary strategy which may prevent many cardiovascular events. In this study we investigated high dose (100 mg/kg b.w./i.p) and time-dependent (2, 7 and 14 days) effects of ASA on the heart key enzymes and substrates from glycogen/glucose metabolism in control and diabetic rats. The results accomplished demonstrated that ASA significantly potentiates glycogen accumulation, as well as decreased blood glucose level and heart glycolytic potential in control rats. The treatment of diabetic rats with ASA caused moderation of the diabetic complication-significant inhibition of glycogen accumulation, lowering of blood glucose, as well as elevation of glycolytic potential. In conclusion, we propose that use of high-dose of ASA has anabolic effects in control rats and reduces heart glycogen glucose complications in diabetic rats. The moderation of diabetes-induced changes is time-dependent and involves reduction of glycogenogenesis and inhibited depression of glycolysis, with a tendency to maintenance control values.
No takes yet. Share an insight, caveat, or question.
Dervisevik et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: